The Bioverativ Inc (NASDAQ:BIVV) Given Average Recommendation of “Hold” by Brokerages

A number of equities research analysts have issued reports on BIVV shares. Argus started coverage on shares of Bioverativ in a report on Friday, March 31st. They set a “hold” rating and a $51.00 price target for the company. Zacks Investment Research upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $61.00 price target for the company in a report on Wednesday, April 5th. Cowen and Company upgraded shares of Bioverativ from a “market perform” rating to an “outperform” rating in a report on Monday, July 10th. Jefferies Group LLC restated a “buy” rating on shares of Bioverativ in a report on Friday, June 30th. Finally, Stifel Nicolaus upped their price target on shares of Bioverativ from $54.00 to $57.00 and gave the company a “buy” rating in a report on Monday, March 27th.

Bioverativ Inc (NASDAQ:BIVV) has received an average rating of “Hold” from the fifteen analysts that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, seven have given a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $56.33.

In related news, insider Diantha Duvall sold 818 shares of the stock in a transaction dated Wednesday, June 28th. The shares were sold at an average price of $60.47, for a total value of $49,464.46. Following the completion of the sale, the insider now owns 2,128 shares in the company, valued at $128,680.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Louis J. Paglia bought 2,000 shares of Bioverativ stock in a transaction that occurred on Friday, May 26th. The stock was bought at an average price of $57.76 per share, with a total value of $115,520.00. Following the purchase, the director now owns 3,056 shares of the company’s stock, valued at approximately $176,514.56. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 94,000 shares of company stock valued at $5,256,940.

Bioverativ (NASDAQ BIVV) opened at 63.62 on Tuesday. The firm has a market cap of $6.88 billion and a PE ratio of 15.56. Bioverativ has a 1-year low of $40.00 and a 1-year high of $63.99. The company has a 50 day moving average price of $60.15 and a 200 day moving average price of $54.89.

About Bioverativ

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.